

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4905578

|   |  |
|---|--|
| <b>SUBMISSION TYPE:</b>   | NEW ASSIGNMENT   |
| <b>NATURE OF CONVEYANCE:</b>  | SECURITY INTEREST  |
| <b>CONVEYING PARTY DATA</b>   |  |
| <b>Name</b>   | <b>Execution Date</b>  |
| OCUNEXUS THERAPEUTICS, INC. (F/K/A CODA THERAPEUTICS, INC.)   | 03/23/2018   |
| <b>RECEIVING PARTY DATA</b>   |  |
| <b>Name:</b>  | PACIFIC WESTERN BANK (AS SUCCESSOR IN INTEREST BY MERGER TO SQUARE 1 BANK) |
| <b>Street Address:</b>  | 406 BLACKWELL STREET   |
| <b>Internal Address:</b>  | SUITE 240  |
| <b>City:</b>  | DURHAM   |
| <b>State/Country:</b>   | NORTH CAROLINA   |
| <b>Postal Code:</b>   | 27701  |
| <b>PROPERTY NUMBERS Total: 7</b>  |  |
| <b>Property Type</b>  | <b>Number</b>  |
| Patent Number:  | 9738892  |
| Patent Number:  | 9457044  |
| Patent Number:  | 9248141  |
| Patent Number:  | 9561311  |
| Application Number:   | 14777458   |
| Application Number:   | 15076513   |
| Application Number:   | 15583898   |
| <b>CORRESPONDENCE DATA</b>  |  |
| <b>Fax Number:</b>  | (919)354-1278  |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |  |
| <b>Phone:</b>   | 9193143114   |
| <b>Email:</b>   | diligencereview@square1bank.com  |
| <b>Correspondent Name:</b>  | PACIFIC WESTERN BANK   |
| <b>Address Line 1:</b>  | 406 BLACKWELL STREET   |
| <b>Address Line 2:</b>  | SUITE 240  |
| <b>Address Line 4:</b>  | DURHAM, NORTH CAROLINA 27701   |
| <b>NAME OF SUBMITTER:</b>   | NICHOLAS NANCE   |
| <b>SIGNATURE:</b>   | /NICHOLAS NANCE-JLT/   |

|   |            |
|---|------------|
| <b>DATE SIGNED:</b>   | 04/09/2018 |
| <b>Total Attachments: 8</b><br>source=Ocunexus - A&R IPSA (March 2018) - Executed#page1.tif<br>source=Ocunexus - A&R IPSA (March 2018) - Executed#page2.tif<br>source=Ocunexus - A&R IPSA (March 2018) - Executed#page3.tif<br>source=Ocunexus - A&R IPSA (March 2018) - Executed#page4.tif<br>source=Ocunexus - A&R IPSA (March 2018) - Executed#page5.tif<br>source=Ocunexus - A&R IPSA (March 2018) - Executed#page6.tif<br>source=Ocunexus - A&R IPSA (March 2018) - Executed#page7.tif<br>source=Ocunexus - A&R IPSA (March 2018) - Executed#page8.tif |            |

**AMENDED AND RESTATED**  
**INTELLECTUAL PROPERTY SECURITY AGREEMENT**

**THIS AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT** is entered into as of March 23, 2018, by and between **PACIFIC WESTERN BANK** (as successor in interest by merger to **Square 1 Bank**), a California state chartered bank ("**Bank**"), and **OCUNEXUS THERAPEUTICS, INC.** (f/k/a **Coda Therapeutics, Inc.**), a Delaware corporation ("**Grantor**").

**RECITALS**

A. Bank has agreed to make certain advances of money and to extend certain financial accommodations to Grantor (the "**Loans**") in the amounts and manner set forth in that certain Loan and Security Agreement by and between Bank and Grantor dated as of March 4, 2009 (as the same may be amended, modified or supplemented from time to time, the "**Loan Agreement**"; capitalized terms used herein are used as defined in the Loan Agreement).

B. Bank is willing to extend and to continue to extend financial accommodations to Grantor, but only upon the condition, among others, that Grantor shall grant to Bank a security interest in certain Copyrights, Trademarks and Patents to secure the obligations of Grantor under the Loan Agreement.

C. Pursuant to the terms of the Loan Agreement, Grantor has granted to Bank a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

**NOW, THEREFORE**, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement and all other agreements now existing or hereafter arising between Grantor and Bank, Grantor hereby represents, warrants, covenants and agrees as follows:

**AGREEMENT**

To secure its obligations under the Loan Agreement and under any other agreement now existing or hereafter arising between Bank and Grantor, Grantor grants and pledges to Bank a security interest in all of Grantor's right, title and interest in, to and under its Intellectual Property (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof (collectively, "**Intellectual Property Collateral**").

This security interest is granted in conjunction with the security interest granted to Bank under the Loan Agreement. The rights and remedies of Bank with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan

Documents, and those which are now or hereafter available to Bank as a matter of law or equity. Each right, power and remedy of Bank provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Bank of any one or more of the rights, powers or remedies provided for in this Amended and Restated Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Bank, of any or all other rights, powers or remedies.

Grantor represents and warrants that Exhibits A, B, and C attached hereto set forth any and all intellectual property rights in connection to which Grantor has registered or filed an application with either the United States Patent and Trademark Office or the United States Copyright Office, as applicable.

**SIGNATURE PAGE FOLLOWS**

IN WITNESS WHEREOF, the parties have caused this Amended and Restated Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

**GRANTOR:**

Address of Grantor:

**OCUNEXUS THERAPEUTICS, INC.**  
(f/k/a Coda Therapeutics, Inc.)

12481 150  
12520 High Bluff Drive, Suite 350  
San Diego, CA 92130

By: 

Name: David Pool

Title: CEO

**BANK:**

Address of Bank:

**PACIFIC WESTERN BANK** (as  
successor in interest by merger to Square  
1 Bank)

406 Blackwell Street, Suite 240  
Durham, NC 27701  
Attn: Loan Documentation Department

By: 

Name: SEAN NOONAN

Title: VICE PRESIDENT

**EXHIBIT A**  
**COPYRIGHTS**

| <u>Description</u> | <u>Registration No.</u> | <u>Registration Date</u> |
|--------------------|-------------------------|--------------------------|
| None.              |                         |                          |

**EXHIBIT B****PATENTS**

| <b>Description</b>   | <b>Application No. /<br/>Issued Patent No.</b> | <b>Application Date /<br/>Filing Date</b> |
|--|--|---|
| Anti-connexin compounds targeted to connexins and methods of use thereof * | 13/230744<br>(8815819)                         | 9/12/2011<br>(8/26/2014)                  |
| Impaired wound healing compositions and treatments *                       | 13/295020<br>(8685940)                         | 11/11/2011<br>(4/1/2014)                  |
| Antisense compounds targeted to connexins and methods of use thereof *     | 10/581813<br>(8034789)                         | 12/3/2004<br>(10/11/2011)                 |
| Wound Healing Compositions and Treatments *                                | 14/214922<br>(9290554)                         | 3/15/2014<br>(3/22/2016)                  |
| Wound Healing Compositions and Treatments *                                | 13/844762<br>(9156896)                         | 3/15/2013<br>(10/13/2015)                 |
| Compositions and Treatments Based On Cadherin Modulation *                 | 13/844553<br>(ABANDONED)                       | 3/15/2013                                 |
| Impaired Wound Healing Compositions and Methods *                          | 13/764674<br>(9029339)                         | 2/11/2013<br>(5/12/2015)                  |
| Formulations Comprising Antisense Nucleotides to Connexins *               | 13/681383<br>(9193754)                         | 11/19/2012<br>(11/24/2015)                |
| Formulations Comprising Antisense Nucleotides to Connexins *               | 7615540  | 11/10/2009                                |
| Formulations Comprising Antisense Nucleotides to Connexins *               | 11/447599<br>(ABANDONED)                       | 6/5/2006                                  |
| Formulations Comprising Antisense Nucleotides to Connexins *               | 8314074  | 11/20/2012                                |
| Formulations Comprising Antisense Nucleotides to Connexins *               | 7098190  | 8/29/2006                                 |
| Formulations Comprising Antisense Nucleotides to Connexins *               | 7879811  | 2/1/2011                                  |

*\*Bank already has an existing Security Interest filed at the USPTO. Such Security Interest will not be refiled upon filing of this Amended and Restated Intellectual Property Security Agreement*

|   |                          |                          |
|---|--------------------------|--------------------------|
| Formulations Comprising Antisense Nucleotides to Connexins *              | 7902164                  | 3/8/2011                 |
| Formulations Comprising Antisense Nucleotides to Connexins *              | 7919474                  | 4/5/2011                 |
| Methods and Compositions For Wound Healing *                              | 8247384                  | 8/21/2012                |
| Formulations Comprising Antisense Nucleotides to Connexins *              | 11/512730<br>(ABANDONED) | 8/29/2006                |
| Impaired Wound Healing Compositions and Treatments *                      | 12/747863<br>(ABANDONED) | 6/11/2010                |
| Treatment of Fibrotic Conditions *  | 12/809974<br>(ABANDONED) | 6/21/2010                |
| Treatment of Orthopedic Conditions *                                      | 12/809980<br>(ABANDONED) | 6/21/2010                |
| Treatment of abnormal or excessive scars *                                | 12/809986<br>(ABANDONED) | 6/21/2010                |
| Treatment of Surgical Adhesions *   | 12/809989<br>(ABANDONED) | 6/21/2010                |
| Medical devices *   | 9035037                  | 5/19/2015                |
| Treatment of fibrotic conditions *  | 8975237                  | 3/10/2015                |
| Impaired wound healing compositions and methods *                         | 14/709382<br>(9637745)   | 05/11/2015<br>(5/2/2017) |
| Wound treatment *   | 14/396722<br>(ABANDONED) | 04/23/2013               |
| Treatment of fibrotic conditions  | 9738892                  | 8/22/2017                |
| Methods and compositions for wound healing                                | 9457044                  | 10/4/2016                |
| Methods of treatment by administering anti-connexin proteins and mimetics | 9248141                  | 2/2/2016                 |



|  |           |           |
|--|-----------|-----------|
| Medical devices                                    | 9561311   | 2/7/2017  |
| Improved wound healing compositions and treatments | 14/777458 | 9/15/2015 |
| Wound healing compositions and treatments          | 15/076513 | 3/21/2016 |
| Impaired wound healing composition and treatments  | 15/583898 | 5/1/2017  |

**EXHIBIT C**  
**TRADEMARKS**

| <b>Description</b> | <b>Serial No. /<br/>Registration No.</b> | <b>Application /<br/>Registration<br/>Date</b> |
|--------------------|--|--|
| NEXAGON*           | 3490217<br>(78602587)                    | 8/19/2008<br>(4/5/2005)                        |
| OCUNEXUS           | 87673865                                 | 11/6/2017                                      |
| XIFLAM             | 87673848                                 | 11/6/2017                                      |

*\*Bank already has an existing Security Interest filed at the USPTO. Such Security Interest will not be refiled upon filing of this Amended and Restated Intellectual Property Security Agreement*